Cagent Vascular has filed a notice of an exempt offering of securities to raise $40,999,992.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Cagent Vascular is raising up to $40,999,992.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Cagent Vascular
Cagent Vascular is the first and only company to commercialize an angioplasty balloon with integrated serrations, introducing a new category of endovascular treatment: Serration Remodeling Therapy (SRT). Headquartered in Wayne, PA, our mission is to improve outcomes for patients with Peripheral Artery Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI) by changing the way physicians treat diseased vessels. Our flagship device, the Serranator PTA Serration Balloon Catheter, creates controlled micro-fissures in the arterial wall, driving vessel wall remodeling, not just dilation. The result: greater lumen gain, reduced recoil, and improved vessel compliance across lesion morphologies. It’s time for a new standard of care. It starts with Serranator.
To learn more, visit https://cagentvascular.com/
LinkedIn: https://www.linkedin.com/company/cagent-vascular/
Contact:
Brian Walsh, Chief Executive Officer
https://www.linkedin.com/in/brianwalsh-medtech/
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.
